SciELO - Scientific Electronic Library Online

 
vol.77 número8Lip height estimation in a southern African sampleDevelopment of a radiographic dental implant guide for identification of dental implant types índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • En proceso de indezaciónSimilares en Google

Compartir


South African Dental Journal

versión On-line ISSN 0375-1562
versión impresa ISSN 0011-8516

Resumen

SINGU, BS  y  SHAAMENA, P. Pharmaceutical cost implications for oral healthcare interventions at a dental clinic in Windhoek, Namibia. S. Afr. dent. j. [online]. 2022, vol.77, n.8, pp.474-477. ISSN 0375-1562.  http://dx.doi.org/10.17159/2519-0105/2022/v77no8a3.

INTRODUCTION: Half of the world's 7.9 billion population suffers from oral health conditions. Most are largely preventable and treatable but costs are often unaffordable especially in developing countries. The World Health Organization (WHO) resolved in 2021 to include oral healthcare interventions in universal healthcare coverage (UHC) programmes. Although the general expenditure on oral healthcare services has been reported by some countries, amounts spent on particularly pharmaceuticals have not been reported AIMS AND OBJECTIVES: This study aimed to report on the prevalence of different types of oral health diseases in patients attending a dental clinic in Windhoek (Namibia) and quantify the pharmaceutical expenditure incurred. METHODS: Records for all patients who visited the dental clinic at KIRH during a six-month period (1 January 2021 to 30 June 2021) were reviewed. Costs associated with the respective pharmaceutical management options for the most common oral conditions were calculated based on the approximated cost for a single treatment course per patient RESULTS: Pharmaceutical expenditure on oral diseases was approximately 0.4% of the hospital's annual budget. From this, 94.6% was due to treatment of dental caries which had a 90.1% prevalence. Prevalence of dental caries among 13-19 years age group (9.5%) was lower than for 1-12 years (18.6%) and 20-64 years (68.2%). Cases for dental caries were fewer for the 65+ years age group (3.8% of total cases) but had the highest prevalence (95.2%) of dental caries then other age groups CONCLUSIONS: The proportion of the pharmaceutical budget spent on treating oral diseases was 0.4%, of which 94.6% was due to dental caries. Promotion of oral healthcare among children may be instrumental in reducing the pharmaceutical costs associated with treatment of dental carries

Palabras clave : oral health; dental caries; universal healthcare; pharmaceuticals; costs; Namibia.

        · texto en Inglés     · Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons